Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Kelly Gaffney, PharmD, Brian P. Hobbs, PhD, Ran Zhao, Marc Earl, PharmD, Marina Feldman, PharmD, BCCCP, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Bhumika J. Patel, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2019) 134 (Supplement_1): 3433.

https://doi.org/10.1182/blood-2019-128807

Published: 2019

Journal Articles

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Julie Kanter, MD, Darla K Liles, MD, Kim Smith-Whitley, MD, Clark Brown, MD PhD, Abdullah Kutlar, MD, Brian Elliott, Amit Shah, Jeremie Lincy, Susan Poggio, Kenneth I. Ataga, MBBS

Blood (2019) 134 (Supplement_1): 991.

https://doi.org/10.1182/blood-2019-123965

Published: 2019

Journal Articles

Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors

Chijioke Nze, MD, Brooke M Fortin, BA, BS, Revital Freedman, PhD, Maneka Puligandla, MS, Donna S Neuberg, ScD, Elyse Mandell, ANP, Maureen Achebe, MD MPH

Blood (2018) 132 (Supplement 1): 4929.

https://doi.org/10.1182/blood-2018-99-119860

Published: 2018

Journal Articles

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Meinolf Karthaus, MD, Matti Aapro, MD, Giada Rizzi, M.Sc., Marco Palmas, MD

Blood (2014) 124 (21): 4821.

https://doi.org/10.1182/blood.V124.21.4821.4821

Published: 2014

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

Feasibility and Prognostic Value of VO2 peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

William A Wood, MD, MPH, Allison M Deal, MS, Claudio L Battaglini, PhD, Bryce B Reeve, PhD, Amy P Abernethy, MD, Yoon Hie Kim, BS, Julia S Whitley, BS, Charlotte Shatten, BS, Robert N Irons, PA, Amber N Essenmacher, PA, Kimberly Wehner, PA, Alicia Pinto, PA, James Coghill, MD, Paul M Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, Don A. Gabriel, MD, PhD, Jonathan S Serody, MD, Thomas C. Shea, MD

Blood (2012) 120 (21): 4152.

https://doi.org/10.1182/blood.V120.21.4152.4152

Published: 2012

Journal Articles

A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results

Anne Hagey, M.D., Jeffrey E. Lancet, MD, Varghese Palath, PhD, Andrew H Wei, MBBS, PhD, Martin Lackmann, PhD, Jorge E. Cortes, Andrew Boyd, MD, PhD, Dan Shochat, PhD, Geoffrey Yarranton, PhD, Christopher Bebbington, DPhil., Jonathan A. Leff, MD

Blood (2011) 118 (21): 4893.

https://doi.org/10.1182/blood.V118.21.4893.4893

Published: 2011

Journal Articles

Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin

C.J. Godfrey, PhD, Christopher H. Cabell, MD, MHS, FACC, Barbara Balser, VMD, Julie Wolfson, MPH, Jean Nichols, PhD, Howard A. Burris, III, MD

Blood (2011) 118 (21): 2680.

https://doi.org/10.1182/blood.V118.21.2680.2680

Published: 2011

Journal Articles

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Robert Delage, MD, MSc, FRCP, A. Robert Turner, MD, FRCPC, Brian Leber, MD, Wanda S. Hasegawa, MD, Denis-Claude Roy, MD, Mary Lynn Savoie, MD, Heather A Leitch, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Donna L. Forrest, MD, Sindu Kanjeekal, MD, Sehdev Sandeep, MD, Pierre Laneuville, MD, Sarit Assouline, MD, Kuljit Grewal, MD, Michael J. Kovacs, MD, FRCPC, Wendy Lam, MD, Annie Woo, M.Sc., Pierre Beauparlant, Ph.D., Jeffrey H. Lipton, MD, PhD

Blood (2011) 118 (21): 4437.

https://doi.org/10.1182/blood.V118.21.4437.4437

Published: 2011

Journal Articles

Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib.

Asifa Malik, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Gloria Mattiuzzi, MD, Gloria Iliescu, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Susan O'Brien

Blood (2010) 116 (21): 4490.

https://doi.org/10.1182/blood.V116.21.4490.4490

Published: 2010

Journal Articles

Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.

Ashraf Z. Badros, MD, Ravi Vij, MD, Thomas Martin, MD, Jeffrey A Zonder, MD, Tina Woo, Zhengping Wang, Susan Lee, Alvin Wong, PharmD, Ruben Niesvizky, MD

Blood (2009) 114 (22): 3877.

https://doi.org/10.1182/blood.V114.22.3877.3877

Published: 2009

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Prevalence, Clinical and Instrumental Correlates of Myocardial Fibrosis and Necrosis by Delayed Contrast Enhancement Cardiovascular Magnetic Resonace in Thalassemia Major Patients

Alessia Pepe, MD, PhD, Brunella Favilli, MSc, Vincenzo Positano, MSc, Marcello Capra, MD, Aurelio Maggio, MD, Carmen Lo Pinto, MD, Anna Spasiano, MD, Gianluca Forni, MD, Aldo Filosa, MD, Caterina Borgna-Pignatti, MD, Paolo Cianciulli, MD, Gaetano Giuffrida, Tommaso Casini, Giorgio Derchi, MD, Massimo Lombardi, MD

Blood (2008) 112 (11): 5424.

https://doi.org/10.1182/blood.V112.11.5424.5424

Published: 2008

Journal Articles

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Blood (2008) 112 (11): 181.

https://doi.org/10.1182/blood.V112.11.181.181

Published: 2008

Journal Articles

The Effect of CAHB on Myelodysplastic Syndrome In Vitro and Its Application in a Prospective Clinical Trial.

Zhen Cai, PhD, MD, Jingsong He, PhD, M.D., Jiming Shi, M.D., Li Li, M.D., Xiaoyan Han, M.D., Qunyi Guo, M.D., Hui Zhou, M.D., Buwen Zhang, M.D., He Huang, PhD, M.D., Maofang Lin, M.D.

Blood (2007) 110 (11): 4628.

https://doi.org/10.1182/blood.V110.11.4628.4628

Published: 2007

Journal Articles

Electrocardiographic Screening for Cardiac Iron in Thalassemia Major.

Jon A. Detterich, MD, Janelle Miller, BS, Thomas D. Coates, MD, PhD, John C. Wood, MD, PhD

Blood (2007) 110 (11): 2766.

https://doi.org/10.1182/blood.V110.11.2766.2766

Published: 2007

Journal Articles

A Phase II Multiple Dose Clinical Trial of Histone Deacetylase Inhibitor ITF2357 in Patients with Relapsed or Progressive Multiple Myeloma: Preliminary Results.

Monica Galli, MD, PhD, Silvia Salmoiraghi, PhD, Josée Golay, PhD, Antonella Gozzini, MD, Alberto Bosi, MD, Claudia Crippa, MD, Giuseppe Rossi, MD, Norbert Pescosta, MD, Sergio Cortelazzo, MD, Alessandra Sechi, PhD, Tiziano Oldoni, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 1175.

https://doi.org/10.1182/blood.V110.11.1175.1175

Published: 2007

Journal Articles

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Youn H. Kim, MD, Sunil Reddy, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Adam Lerner, MD, Mariefrance Demierre, MD, Madeleine Duvic, MD, Sean Whittaker, MD, FRCP, Tadeusz Robak, MD, Jurgen C. Becker, MD, William McCulloch, MB, FRCP, Archibald G. Prentice, MB, FRCP, FRCPath, on behalf of All Investigators

Blood (2007) 110 (11): 123.

https://doi.org/10.1182/blood.V110.11.123.123

Published: 2007

Journal Articles

Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.

Adam Lerner, M.F. Demierre, S. Whittaker, T. Robak, E. Baran, W. McCulloch, A.G. Prentice

Blood (2006) 108 (11): 2468.

https://doi.org/10.1182/blood.V108.11.2468.2468

Published: 2006

Journal Articles

A Phase I, Single and Fractionated, Ascending Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietic Mimetic Antibody Fusion Protein, CNTO528, in Healthy Male Subjects.

K. L. Franson, PharmD, J. Burggraaf, MD, E. A. Bouman-Trio, MD, A. F. Cohen, MD, PhD, B. E. Miller, PhD, H. Jang, PhD, S. J. Marciniak, MBA, E. P.S. van de Ketterij, BS, B. Frederick, BS, Q. Jiao, MS, J. Getsy, DMD, DO, E. H. Bald, BA, H. Walker, BS, A. Schantz, MS, J. A. Ford, BS, K. Mascioli, BS, J. B. Kowalchick, BS

Blood (2005) 106 (11): 4283.

https://doi.org/10.1182/blood.V106.11.4283.4283

Published: 2005

NARROW

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Feasibility and Prognostic Value of VO2 peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results

Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib.

Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Prevalence, Clinical and Instrumental Correlates of Myocardial Fibrosis and Necrosis by Delayed Contrast Enhancement Cardiovascular Magnetic Resonace in Thalassemia Major Patients

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

The Effect of CAHB on Myelodysplastic Syndrome In Vitro and Its Application in a Prospective Clinical Trial.

Electrocardiographic Screening for Cardiac Iron in Thalassemia Major.

A Phase II Multiple Dose Clinical Trial of Histone Deacetylase Inhibitor ITF2357 in Patients with Relapsed or Progressive Multiple Myeloma: Preliminary Results.

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.

A Phase I, Single and Fractionated, Ascending Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietic Mimetic Antibody Fusion Protein, CNTO528, in Healthy Male Subjects.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only